Growth & profitability
- Revenue has grown 53.1% per year over the past 5 years.
- Operating margin has expanded, at -11.3% in the latest year.
SRTA Financials Strata Critical Medical, Inc.
9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $197M | $41M | 20.9% | -11.3% | 14.8% | 12.7% | -$59M | — | $31M |
| 2024 | $147M | -$27M | 20.2% | -15.3% | -12.3% | -10.6% | -$33M | — | $18M |
| 2023 | $225M | -$56M | 18.7% | -30.3% | -23.9% | -19.0% | -$34M | — | $28M |
| 2022 | $146M | -$27M | 15.2% | -36.6% | -9.9% | -8.4% | -$38M | $0 | $41M |
| 2021 | $51M | -$40M | 20.8% | -47.7% | -13.8% | -11.7% | -$16M | — | $7M |
| 2020 | — | -$21M | — | — | -205.3% | -7.4% | — | — | $10M |
| 2020 | $23M | -$10M | 9.9% | -44.2% | -91.7% | -57.4% | -$11M | — | $12M |
| 2019 | — | $2M | — | — | 46.6% | 0.8% | — | — | $1M |
| 2019 | $31M | -$11M | 15.1% | -37.0% | -52.3% | -3.9% | -$11M | — | $22M |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $73M | -$11M | 21.0% | -7.5% | -3.8% | -3.2% | $3M | — | $16M |
| Mar '26 | $67M | $2M | 21.0% | -4.4% | 0.8% | 0.7% | -$1M | — | $59M |
| Dec '25 | $67M | -$9M | 17.5% | -9.6% | -3.2% | -2.7% | -$10M | — | $31M |
| Sep '25 | $49M | $57M | 23.6% | -11.4% | 20.3% | 17.1% | -$40M | — | $23M |
| Jun '25 | $45M | -$4M | 20.0% | -10.3% | -1.7% | -1.5% | -$5M | — | $59M |
| Mar '25 | $36M | -$3M | 19.6% | -15.8% | -1.6% | -1.4% | -$3M | — | $35M |
| Dec '24 | $36M | -$10M | 13.8% | -16.2% | -4.4% | -3.8% | -$6M | — | $18M |
| Sep '24 | $36M | -$2M | 20.8% | -19.7% | -0.8% | -0.7% | -$3M | — | $20M |
| Jun '24 | $68M | -$11M | 24.1% | -17.9% | -4.9% | -4.0% | -$8M | — | $26M |
| Mar '24 | $52M | -$4M | 19.7% | -19.2% | -1.8% | -1.5% | -$16M | — | $37M |
| Dec '23 | $47M | -$34M | 19.0% | -75.1% | -14.5% | -11.5% | -$9M | — | $28M |
| Sep '23 | $71M | $289000 | 21.8% | -10.4% | 0.1% | 0.1% | $1M | — | $37M |
| Jun '23 | $61M | -$12M | 17.0% | -20.0% | -4.7% | -3.8% | -$9M | — | $37M |
| Mar '23 | $45M | -$10M | 15.8% | -28.3% | -3.8% | -3.2% | -$18M | — | $42M |
| Dec '22 | $38M | -$15M | 13.0% | -51.6% | -5.6% | -4.7% | -$9M | $0 | $41M |
| Sep '22 | $46M | -$9M | 20.3% | -22.8% | -3.3% | -2.8% | -$6M | — | $52M |
| Jun '22 | $36M | $8M | 14.3% | -27.3% | 2.9% | 2.6% | -$12M | — | $187M |
| Mar '22 | $27M | -$11M | 11.0% | -51.4% | -3.9% | -3.4% | -$11M | — | $2M |
| Dec '21 | $25M | $772000 | 16.0% | -42.8% | 0.3% | 0.2% | -$6M | — | $3M |
| Sep '21 | $20M | -$9M | 22.0% | -47.9% | -3.2% | -2.7% | -$6M | — | $7M |
Valuation over time
How the market has priced SRTA against its own fundamentals since 2025-08 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has risen from 10.3× (Dec '25) to 11.5× (Sep '26).
- The price-to-sales ratio has fallen from 2.6× (Aug '25) to 2.4× (Sep '26).
P/E
P/S
Frequently asked questions
Is SRTA growing its revenue and profit?
Over the past 5 years, Strata Critical Medical, Inc.'s revenue has grown 53.1% per year. These are computed facts, not advice.
How much debt does SRTA have?
As of FY2025, Strata Critical Medical, Inc. reported — of total debt against $31M of cash.
What is SRTA's profit margin?
In FY2025, gross margin was 20.9%, operating margin -11.3%, and net margin 21.0%.
What is SRTA's P/E ratio?
As of Sep '26, Strata Critical Medical, Inc. traded at a price-to-earnings ratio of about 11.5× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.